Genetic studies over the past few years have identified that over 80% of hunnan melanomas carry mutations in B-Raf or N-Ras oncogenes, which control the MEK/MAPK signaling pathway. It is now apparent that second and third generation inhibitors developed against components of this pathway fail to elicit effective inhibition of melanoma tumor development/progression, highlighting the urgent need to identify additional pathway(s) that are deregulated in this tumor type. Among primary pathways that are likely to augment deregulated MEK/MAPK signaling is the Pten/Akt signaling cascade. In melanoma, 30% of tumors have inactivated Pten and 50% of tumors express a constitutively active Akt. This program project represents a highly integrated approach to translate basic science findings pertaining to the Pten/Akt signaling pathway in melanoma. The overall hypothesis of this proposal is that understanding mechanisms underlying the Pten mediated melanoma tumor development and progression offers unique opportunities for targeting the consequence of its frequent inactivation. To achieve this goal, this Program Project unites an internationally renowned group of collaborators who will cross disciplinary boundaries to provide novel insights into Pten/Akt-mediated melanoma development and to develop new strategies for Pten/Akt-targeted tumor therapy. For the first time we will define the role of the ubiquitin ligase Siah which is upregulated in melanoma and is required for its development and metastasis, as well as identify and characterize metabolic fluxes that are linked to the Pten/Akt pathway. We also propose highly focused efforts in the validation of new drug targets, structure-based drug design, and the identification of molecular signatures to indicate patients that will respond to Ren/Akt-targeted therapy. With the integrated support of the three cores, the three projects will work together to address the following central questions in Pten biology. Project jl: Determine how Pten/Akt regulates tumorigenesis and metastasis through the E3 ligase Siah2. Project 2: Define aspects of central carbon metabolism that are regulated by Pten/Akt, and assess whether these metabolic hubs are valid drug targets in Pten null tumors. Project 3: Use structure-based drug design to develop novel drugs targeting AKT and Siah2. In addition to the administrative core (Core A), support will be provided for siRNA constructs and libraries (Core B), and analysis of human tumor cell lines and TMAs for molecular signatures of markers identified in the course of the proposed studies and for analysis of inhibitors developed against each of the components studied in 2D, 3D cultures and animal rriodel (Core C). Overall, this combination of molecular biology, biochemistry, metabolomics, and structure based drug design offers a second to none opportunity for integrated studies that address critical unanswered questions in tumor biology centered on key tumo[ suppressor gene Pten/Akt with focus on malignant melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA128814-04
Application #
8304387
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (M1))
Program Officer
Spalholz, Barbara A
Project Start
2009-07-22
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
4
Fiscal Year
2012
Total Cost
$2,187,046
Indirect Cost
$1,065,484
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Placzek, Andon N; Prisco, Gonzalo Viana Di; Khatiwada, Sanjeev et al. (2016) eIF2α-mediated translational control regulates the persistence of cocaine-induced LTP in midbrain dopamine neurons. Elife 5:
Bai, Yongsheng; Kinne, Jeff; Donham, Brandon et al. (2016) Read-Split-Run: an improved bioinformatics pipeline for identification of genome-wide non-canonical spliced regions using RNA-Seq data. BMC Genomics 17 Suppl 7:503
Wang, Miao; Kaufman, Randal J (2016) Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature 529:326-35
Han, Jaeseok; Kaufman, Randal J (2016) The role of ER stress in lipid metabolism and lipotoxicity. J Lipid Res 57:1329-38
Feng, Yongmei; Pinkerton, Anthony B; Hulea, Laura et al. (2015) SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. Cancer Res 75:5211-8
Jeon, Young Joo; Khelifa, Sihem; Ratnikov, Boris et al. (2015) Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell 27:354-69
Qi, Jianfei; Ronai, Ze'ev A (2015) Dysregulation of ubiquitin ligases in cancer. Drug Resist Updat 23:1-11
Lau, E; Sedy, J; Sander, C et al. (2015) Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy. Oncogene 34:5739-48
Lau, Eric; Feng, Yongmei; Claps, Giuseppina et al. (2015) The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation. Sci Signal 8:ra124
Senft, Daniela; Ronai, Ze'ev A (2015) UPR, autophagy, and mitochondria crosstalk underlies the ER stress response. Trends Biochem Sci 40:141-8

Showing the most recent 10 out of 39 publications